Personalized treatment for newly diagnosed PTCL based on genetics
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests if choosing treatment based on your lymphoma's genetic profile can improve outcomes for people newly diagnosed with peripheral T-cell lymphoma. It involves analyzing your tumor DNA to find the best therapy for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of peripheral T-cell lymphoma (PTCL).
- You need a tumor sample (fresh or stored) available for genetic testing.
- You must have at least one tumor that can be measured on a PET or CT scan.
- You should be able to care for yourself (ECOG score of 0, 1, or 2).
- Your life expectancy must be at least 3 months.
- You must not have certain other lymphoma types or active cancers, uncontrolled heart or blood vessel disease, serious infections, or be pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a genetic test on your lymphoma tissue to help choose your treatment. It may help personalize therapy for people with newly diagnosed peripheral T-cell lymphoma and see how well the approach works and is tolerated.
This trial tests a combination of three medicines (anti-PD-1, lenalidomide, and azacitidine) for adults with relapsed or refractory peripheral T-cell lymphoma (PTCL) that is measurable or growing. It aims to shrink lymphoma and improve control of the disease when standard treatments haven’t worked or have stopped working.
This trial tests if giving a tailored treatment after first complete remission can improve outcomes for certain types of peripheral T-cell lymphoma. It is for people who have finished initial standard chemotherapy with a complete response.
This trial tests a new combination of drugs (teniposide, a PD-1 checkpoint inhibitor, and selinexor) for people with relapsed or refractory primary central nervous system lymphoma. It aims to see if this three-drug approach can shrink tumors or slow the disease when previous treatments haven't worked.
This Phase 2 trial compares two chemotherapy approaches—adding lenalidomide to CHOP versus CHOP alone—for people with untreated peripheral T-cell lymphoma (PTCL). The goal is to see if the added medicine improves response and safety.
This trial tests a combination of targeted drugs, including an EZH2 inhibitor, for people with peripheral T-cell lymphoma that did not respond to initial chemotherapy. It is designed for patients whose tumor has been genetically tested to guide treatment.
Hear when a new Peripheral T-cell Lymphoma (PTCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.